In Vitro Discordance with In Vivo Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model

  • Monogue M
  • Abbo L
  • Rosa R
  • et al.
N/ACitations
Citations of this article
43Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The management of infections with New Delhi metallo-beta-lactamase-1 (NDM)-producing bacteria remains clinically challenging given the multidrug resistant (MDR) phenotype associated with these bacteria. Despite resistance in vitro , ceftazidime-avibactam previously demonstrated in vivo activity against NDM-positive Enterobacteriaceae . Herein, we observed in vitro synergy with ceftazidime-avibactam and aztreonam against an MDR Klebsiella pneumoniae harboring NDM. In vivo , humanized doses of ceftazidime-avibactam monotherapy resulted in >2 log 10 CFU bacterial reduction; therefore, no in vivo synergy was observed.

Cite

CITATION STYLE

APA

Monogue, M. L., Abbo, L. M., Rosa, R., Camargo, J. F., Martinez, O., Bonomo, R. A., & Nicolau, D. P. (2017). In Vitro Discordance with In Vivo Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 61(7). https://doi.org/10.1128/aac.00486-17

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free